Entrepreneur Briefs

Who needs venture capital? Not Stanford medical researchers whose work shows potential for clinical applications. Last month, Stanford University Hospital announced that it had awarded $351 ,200 to nine projects that need only to be developed a bit further to be ready for clinical testing. These are the first awards made by the hospital under its new technology transfer program, which was announced last summer. In an attempt to speed the transfer of innovative techniques from lab to bedside, th

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Who needs venture capital? Not Stanford medical researchers whose work shows potential for clinical applications. Last month, Stanford University Hospital announced that it had awarded $351 ,200 to nine projects that need only to be developed a bit further to be ready for clinical testing. These are the first awards made by the hospital under its new technology transfer program, which was announced last summer. In an attempt to speed the transfer of innovative techniques from lab to bedside, the hospital has committed $1 ,750,OOO for three-and-a-half years to be used to encourage researchers to find clinical applications for their work. Among the projects that have received funds are a molecular probe for leukemia; a computer system that processes magnetoc resonance images for evaluating heart function and new technology for measuring respiratory functions in seriously ill infants. If these or other projects prove commercially viable, the hospital hopes to put ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies